<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03414840</url>
  </required_header>
  <id_info>
    <org_study_id>2017-2669-001</org_study_id>
    <nct_id>NCT03414840</nct_id>
  </id_info>
  <brief_title>Assessment of Change in Atherosclerotic Plaque by Serial CCTA</brief_title>
  <acronym>ACROSS</acronym>
  <official_title>Assessment of Change in Atherosclerotic Plaque by Serial CCTA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chong Kun Dang Pharmaceutical Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of Change in AtheROSclerotic Plaque by Serial CCTA (ACROSS) is designed as a
      prospective observational study which aim is to demonstrate the effect of statins on coronary
      atherosclerosis, assessed by quantitative analysis of CCTA.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2018</start_date>
  <completion_date type="Anticipated">October 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in percent change of total atheroma volume assessed by CCTA between statin-taking and statin-naïve group</measure>
    <time_frame>24 months</time_frame>
    <description>Patients indicated with statin therapy according to current guideline will receive atorvastatin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of total atheroma volume at 24 months compared with baseline total atheroma volume</measure>
    <time_frame>24 months</time_frame>
    <description>total atheroma volume assessed by CCTA</description>
  </secondary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Hydroxymethylglutaryl-CoA Reductase Inhibitors</condition>
  <condition>Coronary Arteriosclerosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Patients diagnosed with coronary artery disease by CCTA be enrolled. Among enrolled patients, patients who is indicated to statin treatment according to the current ACC/AHA guideline will be treated with atorvastatin.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who underwent clinically indicated CCTA and confirmed to have coronary
        atherosclerosis will be enrolled.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who underwent clinically indicated CCTA (index CCTA)

          -  Mild to moderate stenosis (25-69%) on CCTA

          -  ≥1 clinical risk factors (Smoking, HTN, HDL&lt;40, Premature FHx, M ≥45, F ≥55) for CAD

        Exclusion Criteria:

          -  Acute coronary syndrome (unstable angina or MI)

          -  Positive (not equivocal) stress test

          -  Contraindications to statin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyuk-Jae Chang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyuk-Jae Chang, MD, PhD</last_name>
    <phone>+82-2-2228-8454</phone>
    <email>hjchang@yuhs.ac</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sang-Eun Lee, MD, PhD</last_name>
    <email>tkddmss@yuhs.ac</email>
  </overall_contact_backup>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2018</study_first_submitted>
  <study_first_submitted_qc>January 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2018</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yonsei University</investigator_affiliation>
    <investigator_full_name>Hyuk-Jae Chang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>coronary artery disease</keyword>
  <keyword>coronary computed tomography angiography</keyword>
  <keyword>statins</keyword>
  <keyword>coronary atherosclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Plaque, Atherosclerotic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

